Loading
Leftover-cancer blood tests are being sold faster than evidence that acting on them helps. Paying for them only when the result is recorded would generate the missing evidence.
MRD testing is spreading through routine care ahead of randomised evidence that intervention on a positive result improves survival. Coverage with evidence development (reimbursement conditional on enrolment in a registry or trial with mandatory outcome submission) turns uncontrolled adoption into a data-generating engine, as it has for some devices and PET indications.
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares SEER (Surveillance, Epidemiology, and End Results), ClinicalTrials.gov, Real-world evidence, Weak real-world evidence and registries.
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Incentives reward me-too drugs and marginal gains.
Shares SEER (Surveillance, Epidemiology, and End Results), Real-world evidence, Weak real-world evidence and registries.
Shares SEER (Surveillance, Epidemiology, and End Results), Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Real-world evidence, Weak real-world evidence and registries.